Anavex Life Sciences Corp. — Form 10-Q Summary
Reporting period: Quarter and six months ended March 31, 2023, the company’s fiscal second quarter. The unaudited statements are prepared under U.S. GAAP. Anavex is a clinical-stage biopharmaceutical company developing CNS disease candidates, principally ANAVEX 2-73 (blarcamesine). It has not generated operating revenue.
Financial results and liquidity
| Metric | Three months ended March 31, 2023 | Prior-year quarter | Six months ended March 31, 2023 | Prior-year six months |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $11.3 million | $8.6 million | $23.4 million | $17.3 million |
| General and administrative expense | $2.9 million | $2.9 million | $6.2 million | $6.0 million |
| Total operating expenses | $14.2 million | $11.5 million | $29.6 million | $23.2 million |
| Net loss | $13.1 million | $10.4 million | $26.1 million | $21.3 million |
| Loss per share, basic and diluted | $0.17 | $0.14 | $0.33 | $0.28 |
| Net cash used in operating activities | Not stated by quarter | $14.3 million | $13.1 million |
- Cash and cash equivalents were $153.5 million at March 31, 2023, up from $149.2 million at September 30, 2022. Working capital was $145.2 million, versus $142.5 million at fiscal year-end.
- Current liabilities were $14.0 million; total liabilities were $14.0 million. The filing reports no debt balance. Gross margin is not applicable because the company had no product revenue.
- Six-month financing cash inflow was $18.6 million, primarily from issuing shares under the February 2023 Lincoln Park purchase agreement. Cash increased by $4.3 million over the six months.
Changes versus comparable periods
- Quarterly and six-month net losses widened year over year, mainly due to increased R&D spending. Six-month R&D expense rose about 35%, reflecting higher external-provider costs, staffing and stock-based compensation, manufacturing activity for ANAVEX 2-73 and 3-71, and enrollment in the EXCELLENCE Rett syndrome trial.
- Interest income increased materially with returns on cash investments. Six-month net other income rose to $3.5 million from $2.0 million; the current-year quarter included a one-time $964,344 financing expense related to the Lincoln Park agreement.
- Common shares outstanding rose from 77.9 million at September 30, 2022 to 80.2 million at March 31, 2023. The company issued 2.075 million purchase shares for $18.2 million and commitment shares under the agreement.
Outlook, programs and risks
- Management believes available working capital will fund requirements for more than 12 months after issuance of the statements. The company expects operating cash outflows to continue and anticipates higher R&D spending as it advances clinical programs, including ANAVEX 2-73, planned Parkinson’s disease work, a planned Fragile X program, extension studies and ANAVEX 3-71. Profitability timing is uncertain.
- Management reported positive topline results from the completed Phase 2b/3 Alzheimer’s trial in December 2022, stating that ANAVEX 2-73 met co-primary ADAS-Cog and ADCS-ADL endpoints and the key secondary CDR-SB endpoint. These are company-reported trial results, not regulatory approval.
- The pediatric EXCELLENCE Rett syndrome trial completed enrollment in February 2023; topline results were expected in the second half of 2023. Preliminary Parkinson’s disease extension data were reported in March 2023. The filing describes these results as preliminary.
- The $150 million Lincoln Park purchase agreement runs through February 3, 2026; $131.8 million remained available at March 31, 2023. Share issuance is at the company’s discretion and may dilute existing shareholders. A separate at-the-market facility had $142.4 million registered and available, with no shares sold under it in the six months.
- Key risks include clinical-trial execution, safety and efficacy, regulatory outcomes, reliance on third-party trial providers, intellectual-property protection, competition, and the possibility that additional financing may not be available on acceptable terms. Australian R&D tax-incentive claims for 2018–2022 remain subject to potential review or audit. The company reported no material changes to its prior annual-report risk factors.
- Ordinary-course legal claims are disclosed; management did not believe pending matters would materially adversely affect the financial statements. No material pending legal proceedings were identified in Part II. Disclosure controls were deemed effective as of March 31, 2023.
Important facts for investors to verify
- Review the full Alzheimer’s Phase 2b/3 results, statistical methods, prespecified analyses and subsequent regulatory discussions; topline statements in this filing are company-reported.
- Check whether anticipated EXCELLENCE results and planned Parkinson’s and Fragile X development steps occurred, and assess resulting trial costs and timelines.
- Track cash burn against the stated greater-than-12-month liquidity outlook, including changes in R&D spending and operating cash use.
- Monitor share issuance under the Lincoln Park agreement and the available at-the-market facility, including dilution and remaining capacity.
- Follow Australian tax-incentive eligibility reviews and any material developments in legal matters or other contingencies.